---
schema_version: "secwatch.filing_event.v1"
accession: "0001411685-24-000059"
form_type: "8-K"
ticker: "VTGN"
cik: "0001411685"
company_name: "Vistagen Therapeutics, Inc."
filed_at: "2024-12-06T23:59:59+00:00"
generated_at: "2026-05-29T06:16:08.213752+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "low"
source: SEC EDGAR
---

# Vistagen posts new corporate presentation; no specific financial updates

## Summary
- Company released an updated corporate presentation on December 6, 2024.
- Tagline: 'Pioneering neuroscience with nose-to-brain neurocircuitry'.
- No new financial guidance, clinical results, or material transactions disclosed.

## SEC filing metadata
- accession: 0001411685-24-000059
- form_type: 8-K
- ticker: VTGN
- cik: 0001411685
- company_name: Vistagen Therapeutics, Inc.
- filed_at: 2024-12-06T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: low
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1411685/000141168524000059/0001411685-24-000059-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1411685/000141168524000059/vtgn-20241206.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001411685-24-000059
- JSON: https://secwatch.observer/filing/0001411685-24-000059.json
- Plain text: https://secwatch.observer/filing/0001411685-24-000059.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.